Cargando…
Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe?
Objective COVID-19 has been negatively impacted by a number of comorbidities. Aside from that, some conditions or treatments that cause immunosuppression can alter the course of the disease, leading to worse outcomes. The primary goal of this study is to compare the clinical presentation, laboratory...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186853/ https://www.ncbi.nlm.nih.gov/pubmed/37200662 http://dx.doi.org/10.7759/cureus.37633 |
_version_ | 1785042636077268992 |
---|---|
author | Olgun Yıldızeli, Sehnaz Vezir, Duygu Cimsit, Canan Kocakaya, Derya Mercanci, Zeynep Balcan, Baran Ermerak, Onur Ilgin, Can Eryuksel, Emel Karakurt, Sait |
author_facet | Olgun Yıldızeli, Sehnaz Vezir, Duygu Cimsit, Canan Kocakaya, Derya Mercanci, Zeynep Balcan, Baran Ermerak, Onur Ilgin, Can Eryuksel, Emel Karakurt, Sait |
author_sort | Olgun Yıldızeli, Sehnaz |
collection | PubMed |
description | Objective COVID-19 has been negatively impacted by a number of comorbidities. Aside from that, some conditions or treatments that cause immunosuppression can alter the course of the disease, leading to worse outcomes. The primary goal of this study is to compare the clinical presentation, laboratory analysis, radiological findings, and outcomes of patients with COVID-19 with and without immunosuppression. Materials and methods The study includes patients with pre-existing immunosuppression and COVID-19 infection who were admitted and received inpatient treatment at Marmara University Hospital, Istanbul, Pulmonary Medicine ward between April 2020 and June 2020. Data on demographics, epidemiology, clinical course, laboratory analysis, radiological findings, length of hospital stay, morbidity, and mortality were collected from all patients. Results The study group consisted of 23 patients who had pre-existing immunosuppression, and the control group consisted of 207 immunocompetent patients, making a total of 230 patients. Significant differences in lymphocyte count, ROX (respiratory-rate oxygenation) index on Day 0, and fibrinogen levels were discovered between the two groups. SARI (severe acute respiratory infection) was more common in the control group than in the study group (p<0.022), but there was no difference in mortality. Conclusion The mean number and percentage of lymphocytes were lower in immunocompromised COVID-19 patients at the time of diagnosis. Higher ROX index values and a lower risk of developing SARI could explain the hypothesis that these patients may be benefiting from a pre-existing corticosteroid regimen. Additional research with larger numbers of patients may be beneficial in drawing a more definitive conclusion. |
format | Online Article Text |
id | pubmed-10186853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-101868532023-05-17 Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? Olgun Yıldızeli, Sehnaz Vezir, Duygu Cimsit, Canan Kocakaya, Derya Mercanci, Zeynep Balcan, Baran Ermerak, Onur Ilgin, Can Eryuksel, Emel Karakurt, Sait Cureus Infectious Disease Objective COVID-19 has been negatively impacted by a number of comorbidities. Aside from that, some conditions or treatments that cause immunosuppression can alter the course of the disease, leading to worse outcomes. The primary goal of this study is to compare the clinical presentation, laboratory analysis, radiological findings, and outcomes of patients with COVID-19 with and without immunosuppression. Materials and methods The study includes patients with pre-existing immunosuppression and COVID-19 infection who were admitted and received inpatient treatment at Marmara University Hospital, Istanbul, Pulmonary Medicine ward between April 2020 and June 2020. Data on demographics, epidemiology, clinical course, laboratory analysis, radiological findings, length of hospital stay, morbidity, and mortality were collected from all patients. Results The study group consisted of 23 patients who had pre-existing immunosuppression, and the control group consisted of 207 immunocompetent patients, making a total of 230 patients. Significant differences in lymphocyte count, ROX (respiratory-rate oxygenation) index on Day 0, and fibrinogen levels were discovered between the two groups. SARI (severe acute respiratory infection) was more common in the control group than in the study group (p<0.022), but there was no difference in mortality. Conclusion The mean number and percentage of lymphocytes were lower in immunocompromised COVID-19 patients at the time of diagnosis. Higher ROX index values and a lower risk of developing SARI could explain the hypothesis that these patients may be benefiting from a pre-existing corticosteroid regimen. Additional research with larger numbers of patients may be beneficial in drawing a more definitive conclusion. Cureus 2023-04-16 /pmc/articles/PMC10186853/ /pubmed/37200662 http://dx.doi.org/10.7759/cureus.37633 Text en Copyright © 2023, Olgun Yıldızeli et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Infectious Disease Olgun Yıldızeli, Sehnaz Vezir, Duygu Cimsit, Canan Kocakaya, Derya Mercanci, Zeynep Balcan, Baran Ermerak, Onur Ilgin, Can Eryuksel, Emel Karakurt, Sait Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? |
title | Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? |
title_full | Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? |
title_fullStr | Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? |
title_full_unstemmed | Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? |
title_short | Pre-existing Immunocompromised Status as a Preventer of Mortality in COVID-19 Patients: Friend or Foe? |
title_sort | pre-existing immunocompromised status as a preventer of mortality in covid-19 patients: friend or foe? |
topic | Infectious Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186853/ https://www.ncbi.nlm.nih.gov/pubmed/37200662 http://dx.doi.org/10.7759/cureus.37633 |
work_keys_str_mv | AT olgunyıldızelisehnaz preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT vezirduygu preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT cimsitcanan preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT kocakayaderya preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT mercancizeynep preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT balcanbaran preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT ermerakonur preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT ilgincan preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT eryukselemel preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe AT karakurtsait preexistingimmunocompromisedstatusasapreventerofmortalityincovid19patientsfriendorfoe |